Nuclear Pore Protein p62 Autoantibodies in Systemic Lupus Erythematosus



Doris M Kraemer*, 1, Hans-Peter Tony2
1 Queen’s Cancer Centre, Hull, UK
2 Medizinische Klinik and Poliklinik II, University of Wuerzburg, Germany


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 755
Abstract HTML Views: 249
PDF Downloads: 102
Total Views/Downloads: 1106
Unique Statistics:

Full-Text HTML Views: 358
Abstract HTML Views: 169
PDF Downloads: 88
Total Views/Downloads: 615



© Kraemer and Tony; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Haematology Department, Queen Cancer Centre of Oncology and Haematology, Castle Road, Cottingham, HU16 5JQ, UK; Tel: (44) 01482 461291; Fax: (44) 01482 607739; E-mail: Doris.Kraemer@hey.nhs.uk


Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease which is classically characterised by a variety of autoantibodies to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), other nuclear and cytoplasmic antigens. Recently several novel autoantibodies against a variety of specific nuclear pore proteins have been described, including the nucleoporin p62. In this paper we evaluate anti-nucleoporin p62 antibodies by western blot analysis in 25 systemic lupus erythematosus patients. Six patients showed antibodies directed against nucleoporin p62. Our data indicate that p62 antibodies could be a useful additional marker in SLE.

Keywords: Systemic lupus erythematosus, autoantibodies, nucleoporin p62..